News

Press release

TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box

Mar 24, 2026

Download document ⤓

Read more
TempraMed’s Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

Mar 11, 2026

Download document ⤓

Read more
TempraMed Reports Over 275 Clinicians Sharing VIVI Cap to Patients on Leading FrontrowMD Platform across the United States

Feb 26, 2026

Download document ⤓

Read more
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel

Feb 06, 2026

Download document ⤓

Read more
TempraMed Enters Strategic Media Partnership with Dr. Phil’s Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States

Feb 02, 2026

Download document ⤓

Read more
TempraMed Launches New Product “VIVI Med", Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications

Jan 23, 2026

Download document ⤓

Read more
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage

Jan 14, 2026

Download document ⤓

Read more
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Jan 12, 2026

Download document ⤓

Read more

© 2026 Tempramed • Terms of Use • Privacy Policy • Return Policy • Shipment Delivery

Secure Checkout: secure-amex

secure-amex

secure-mastercard

secure-paypal

secure-applepay

secure-jcb

secure-visa

secure-discover

secure-shoppay

secure-klarna

secure-afterpay

secure-affirm

secure-fsa

secure-hsa

Any information on this website is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Always consult a healthcare professional before making health-related decisions.